Literature DB >> 26712223

ABVD or BEACOPP for Advanced Hodgkin Lymphoma.

Andreas Engert1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26712223     DOI： 10.1200/JCO.2015.64.8683

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Authors:  Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

2.  Tumor necrosis factor receptor 2 may promote the proliferation and drug resistance of Kapras299 and L428 lymphoma cells via the AKT and WNT/β-catenin signaling pathways.

Authors:  Yanyan Liang; Yu Wang; Meng Xiao; Yunliang Hao; Yongtian Zhang; Shumei Li
Journal:  Oncol Lett       Date:  2018-03-30       Impact factor: 2.967

Review 3.  Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma.

Authors:  Craig Moskowitz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment.

Authors:  Niloufer Khan; Joseph Feliciano; Kerstin Müller; Mary He; Rei Tao; Ellen Korol; Mehul Dalal; Mayvis Rebeira; Matthew Matasar
Journal:  Leuk Lymphoma       Date:  2020-07-20

5.  Comparative effectiveness of different chemotherapy regimens of advanced-stage Hodgkin lymphoma in adults: a network meta-analysis.

Authors:  Tingting Zhang; Yan Yao; Fubin Feng; Wenge Zhao; Jinhui Tian; Chao Zhou; Xue Wang; Shengjie Dong; Jia Li; Lingyu Qi; Changgang Sun
Journal:  Cancer Manag Res       Date:  2018-11-22       Impact factor: 3.989

6.  SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment.

Authors:  Mariana Bastos Oreiro; Reyes Martín; Pilar Gomez; Nieves López Muñoz; Antonia Rodriguez; Marta Liébana; Belén Navarro; Blanca Sánchez-González; Pilar Marí; Jaime Pérez de Oteiza; Antonio Gutiérrez; Leyre Bento; Eva Domingo Doménech; María Jesús Vidal; Raquel Del Campo; Elena Pérez Ceballos; María Infante; Alicia Roldán; Daniel García Belmonte; Miriam Santero; Anna Sureda; Ramón García Sanz
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

Review 7.  Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas.

Authors:  Jungang Chen; Samantha Kendrick; Zhiqiang Qin
Journal:  Viruses       Date:  2019-12-16       Impact factor: 5.048
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.